Baloxavir Marboxil

2025年3月27日，NMPA官网宣布，批准江西科睿药业有限公司申报的1类创新药玛舒拉沙韦片（受理号：CXHS2300106），用于既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。公开资料显示，该药由青峰医药与银杏树药业联合开发，科睿药业为青峰医药子公司。玛舒拉沙韦片是我国首个靶向流感病毒聚合酶酸性蛋白（PA）的抗流感药物，与罗氏制药的玛巴洛沙韦作用机制一致。【作用机理】流感病毒作为负链RNA病毒，入侵宿主细胞后并不能以自身为模板直接进行复制和转录，而是先合成互补的mRNA（包括cRNA），随后再进行转录/翻译及组装过程。在病毒入侵宿主细胞后，新形成的病毒mRNA并不具备完整功能，需要进行修饰。修饰后具有可供宿主细胞翻译体识别的5'-帽状结构（CAP）、3'-poly(A)尾结构，并进行碱基修饰后方可具有完整转录/翻译功能。流感病毒本身不能合成/不具有5'-帽状结构引物。其聚合酶中的PA亚基中的帽依赖性核酸内切酶可识别宿主细胞的前体mRNA，并将宿主前体mRNA中的帽状结构（CAP）剪切掉并“抢来”，拼接到病毒mRNA上，如此一来，病毒mRNA就具有了完整的功能。“抢帽（cap-snatching）”过程是流感病毒转录/翻译起始所必须。玛舒拉沙韦是一种前药，其通过水解转化为活性代谢产物GP1707D07，选择性抑制流感病毒PA的帽依赖性核酸内切酶，从而抑制流感病毒的复制。【临床研究】2025年1月，青峰医药宣布，玛舒拉沙韦片的Ⅲ期临床研究数据（NCT05474755）在Nature Medicine发表。这是一项多中心、分层随机、双盲、安慰剂平行对照 III 期临床研究，共纳591名患者，包含约80%的成年人和20%的儿童及青少年。在抗病毒疗效方面，与安慰剂相比，玛舒拉沙韦在用药后第1天的病毒载量从基线下降速度更快，玛舒拉沙韦组病毒载量的平均变化为-2.2 ± 1.3 log10 copies/ml，安慰剂组为-1.3 ± 1.7 log10 copies/ml(P < 0.001)。研究结果显示，中位流感症状缓解时间和中位病毒清除时间相比安慰剂组，分别缩短21小时和25小时，且无严重不良事件病例报告，安全有效。玛舒拉沙韦片作为一种全新作用机制的核酸内切酶抑制剂，具有疗效强、剂量低、耐药性好等特点，能更早干预病毒生命周期，直接阻碍成熟病毒的形成，患者全病程只需服药一次。在玛舒拉沙韦片还未上市前，目前国内可用的流感抗病毒药物主要包括：玛巴洛沙韦、奥司他韦、阿比多尔、扎那米韦和帕拉米韦等，除了玛巴洛沙韦全病程只需给药一次外，其他4款均需要连续使用5天。叮当快药数据显示，近期呼吸道疾病用药销量持续走高，奥司他韦、玛巴洛沙韦的销售增长率均超过160%。青峰医药称，公司正在研究开发玛舒拉沙韦片预防流感的适应症，同时也在推动更适合低龄儿童服用的新剂型的开发。曾有新闻稿指出，玛舒拉沙韦上市后潜在年销售额有望超过20亿元。Ref:1、Wang, Y., Wang, H., Zhang, Y. et al. Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 31, 639–646 (2025). https://doi.org/10.1038/s41591-024-03419-32、青峰医药官网3、求实药社4、叮当快药数据统计药事纵横投稿须知：稿费已上调，欢迎投稿

BOTHELL, Wash., March 31, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the 12 months ended December 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “Our novel, potent antiviral compounds for norovirus, influenza and coronavirus address critical gaps in global health where effective treatments or vaccines are currently lacking,” said Sam Lee, Ph.D., President and co-CEO of Cocrystal. “We plan to initiate a norovirus human challenge study in the U.S. later this year to evaluate our pan-viral protease inhibitor CDI-988 for the potential treatment and prevention of norovirus infection. The big surge in reported norovirus outbreaks is possibly due to norovirus variants switching from GII.4 to GII.17, as well as increased social gathering after the COVID-19 pandemic. Norovirus is the most common cause of acute gastroenteritis and there are no approved therapeutics or vaccines, making it a compelling target. “We are optimistic that our oral PB2 inhibitor CC-42344 will have potential as a treatment for seasonal influenza A infection and pandemic avian influenza,” he added. “Following the unexpected low infection rate from the Phase 2a challenge study that precluded us from obtaining meaningful human efficacy data, we plan to continue the influenza challenge study.” “News coverage in recent months of norovirus and avian flu outbreaks underscore the urgent need for new antiviral solutions,” said James Martin, CFO and co-CEO of Cocrystal. “We are advancing our first- and best-in-class antiviral drug compounds that were designed using our Nobel Prize-winning structure-based technologies for these high-value viral targets that address multibillion-dollar markets.” Antiviral Product Pipeline Overview We apply our proprietary structure-based drug discovery platform technology for developing broad-spectrum antivirals that inhibit viral replication. By designing and selecting candidates that target highly conserved regions of the viral enzymes, we seek to develop drugs that are effective against the virus and mutations of the virus, while reducing off-target interactions that may cause undesirable side effects. Our drug discovery process differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes. Influenza Programs Influenza is a major global health threat that may become more challenging to treat due to the emergence of highly pathogenic avian influenza viruses and resistance to approved influenza antivirals. Each year there are approximately 1 billion cases of seasonal influenza worldwide, 3-5 million severe illnesses and up to 650,000 deaths. On average, about 8% of the U.S. population contracts influenza each season. In addition to the health risk, influenza is responsible for an estimated $11.2 billion in direct and indirect costs in the U.S. annually. Oral CC-42344 for the treatment of pandemic and seasonal influenza A Our novel PB2 inhibitor CC-42344 showed excellent in vitro antiviral activity against pandemic and seasonal influenza A strains, as well as strains that are resistant to Tamiflu® and Xofluza®.In December 2022 we reported favorable safety and tolerability results from the oral CC-42344 Phase 1 study.In December 2023 we began a randomized, double-blind, placebo-controlled Phase 2a human challenge study to evaluate the safety, tolerability, viral and clinical measurements of CC-42344 in influenza A-infected subjects in the United Kingdom, following authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA).In May 2024 we completed enrollment in the Phase 2a human challenge study.In June 2024 we reported that in vitro studies demonstrated CC-42344 inhibits the activity of the highly pathogenic avian influenza A (H5N1) PB2 protein identified in humans exposed to infected dairy cows.In December 2024 we announced a plan to extend the CC-42344 human challenge study due to unexpectedly low influenza infection among study participants. Inhaled CC-42344 as prophylaxis and treatment for pandemic and seasonal influenza A Our preclinical testing showed superior pulmonary pharmacology with CC-42344 including high exposure to drug and a long half-life.We have completed CC-42344 inhalation formulation development and GLP toxicology studies. Influenza A/B program Our efforts to develop a preclinical lead of novel influenza replication inhibitors are ongoing. Norovirus Program Norovirus symptoms can include severe nausea, vomiting and diarrhea. An estimated 685 million cases and an estimated 50,000 child deaths worldwide are attributed to norovirus each year, with an estimated societal cost of $60 billion. By targeting viral replication, we believe it is possible to develop an effective treatment and/or prophylaxis for closed environments for all genogroups of norovirus. Oral pan-viral protease inhibitor CDI-988 for the treatment of noroviruses and coronaviruses Our novel, broad-spectrum protease inhibitor CDI-988 is being evaluated as a potential oral treatment for noroviruses and coronaviruses.CDI-988 has shown in vitro pan-viral activity against multiple norovirus strains.In May 2023 we announced approval of our application to the Australian regulatory agency for a randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety, tolerability and pharmacokinetics (PK) of oral CDI-988 in healthy volunteers.In August 2023 we announced our selection of CDI-988 as our lead compound for the oral treatment for noroviruses, in addition to coronaviruses.In July 2024 we reported favorable safety and tolerability results from the single-ascending dose cohorts in the Phase 1 study.In December 2024 we reported favorable safety and tolerability results from the multiple-ascending dose cohorts of the Phase 1 study and the addition of a higher-dose cohort.We expect to report topline results from the high-dose healthy volunteer cohort with CDI-988 in the second quarter of 2025.We plan to initiate a human challenge study in the U.S. in 2025 to evaluate CDI-988 as a norovirus treatment and prophylaxis. SARS-CoV-2 and Other Coronavirus Programs By targeting viral replication enzymes and proteases, we believe it is possible to develop effective treatments for all diseases caused by coronaviruses including SARS-CoV-2 and its variants, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). CDI-988 showed potent in vitro pan-viral activity against common human coronaviruses, rhinoviruses and respiratory enteroviruses, as well as against noroviruses. The global COVID-19 therapeutics market is estimated to exceed $16 billion annually by the end of 2031. Oral pan-viral protease inhibitor CDI-988 for the treatment of coronaviruses and noroviruses CDI-988 exhibited superior in vitro potency against SARS-CoV-2 and demonstrated a favorable safety profile and PK properties.In September 2023 we dosed the first healthy subject in our dual pan-norovirus/pan-coronavirus oral CDI-988 study, which is expected to serve as a Phase 1 study for both indications.In July 2024 we reported favorable safety and tolerability results from the single-ascending dose cohort in the Phase 1 study.In December 2024 we reported favorable safety and tolerability results from the multiple-ascending dose cohorts of the Phase 1 study and the addition of a higher-dose cohort.We expect to report topline results from the higher dose cohort in the CDI-988 Phase 1 study in the second quarter of 2025. 2024 Financial Results Research and development (R&D) expenses for 2024 were $12.5 million, compared with $15.2 million for 2023. The decrease was primarily due to the timing of clinical study costs. General and administrative (G&A) expenses for 2024 were $5.3 million, compared with $6.0 million for 2023, with the $0.7 million decrease primarily due to a reduction of insurance costs and other expenses. During 2023 the Company received $2.6 million related to litigation with an insurer. The net loss for 2024 was $17.5 million, or $1.72 per share, compared with the net loss for 2023 of $18.0 million, or $1.87 per share. For 2024 the year over-year-net loss was reduced by $3.1 million exclusive of the $2.6 million received in 2023 noted above. Cocrystal reported unrestricted cash as of December 31, 2024 of $9.9 million, compared with $26.4 million as of December 31, 2023. Net cash used in operating activities for 2024 was $16.5 million, compared with $14.7 million for 2023. The Company had working capital of $9.2 million and 10.2 million common shares outstanding as of December 31, 2024. About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. For further information about Cocrystal, please visit www.cocrystalpharma.com. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans for the future development of preclinical and clinical product candidates, our expectations regarding future characteristics of the product candidates we develop, the expected time of achieving certain value-driving milestones in our programs, including preparation, commencement and advancement of clinical studies for certain product candidates in 2025, our plans regarding further clinical development of such product candidates, and the viability and efficacy of potential treatments for diseases our product candidates are designed to treat, and expectations for the markets for certain therapeutics. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from our need for additional capital to fund our operations over the next 12 months, inflation, the possibility of a recession, interest rate increases, imposed and threated tariffs, and geopolitical conflicts including those in Ukraine and Israel on our Company, our collaboration partners, and on the U.S., UK, Australia and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials for and otherwise proceed with studies as well as similar problems with our vendors and our current and any future clinical research organization (CROs) and contract manufacturing organizations (CMOs), the progress and results of the studies for CC-42344 and CDI-988 including the delay of the Phase 2a study for CC-42344 which may require us to incur substantial additional costs, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes including potential downward pressure on government spending on the biopharmaceutical and healthcare industry based on policies and actions taken by the Trump Administration in the U.S., the impact of the Trump Administration’s policies and actions on regulation affecting the FDA and other healthcare agencies and potential staffing issues resulting therefrom, potential mutations in a virus we are targeting that may result in variants that are resistant to a product candidate we develop, and the potential for the development of effective treatments by competitors which could reduce or eliminate a prospective future market share commercializing any product candidates we may develop in the future. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Investor Contact:Alliance Advisors IRJody Cain310-691-7100jcain@allianceadvisors.com Financial Tables to follow COCRYSTAL PHARMA, INC. CONSOLIDATED BALANCE SHEETS(in thousands) December 31, 2024 December 31, 2023 Assets Current assets: Cash $9,860 $26,353 Restricted cash 75 75 Tax credit receivable 1,215 890 Prepaid expenses and other current assets 430 1,773 Total current assets 11,580 29,091 Property and equipment, net 153 271 Deposits 29 46 Operating lease right-of-use assets, net (including $152 and $42 to related party) 1,694 1,851 Total assets $13,456 $31,259 Liabilities and stockholders’ equity Current liabilities: Accounts payable and accrued expenses $2,127 $3,022 Current maturities of operating lease liabilities (including $49 and $42 to related party) 301 240 Total current liabilities 2,428 3,262 Long-term liabilities: Operating lease liabilities (including $104 and $0 to related party) 1,505 1,613 Total long-term liabilities 1,505 1,613 Total liabilities 3,933 4,875 Commitments and contingencies Stockholders’ equity: Common stock $0.001 par value; 100,000 and 150,000 shares authorized as of December 31, 2024 and 2023, respectively; 10,174 shares issued and outstanding as of December 31, 2024 and 2023, respectively 10 10 Additional paid-in capital 342,931 342,288 Accumulated deficit (333,418) (315,914)Total stockholders’ equity 9,523 26,384 Total liabilities and stockholders’ equity $13,456 $31,259 COCRYSTAL PHARMA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share data) December 31, 2024 2023 Operating expenses: Research and development $12,537 $15,169 General and administrative 5,341 5,990 Legal settlement - (2,600)Total operating expenses 17,878 18,559 Loss from operations (17,878) (18,559) Other income (expense): Interest income, net 537 640 Foreign exchange loss (163) (65)Total other income, net 374 575 Net loss $(17,504) $(17,984) Net loss per common share, basic and diluted $(1.72) $(1.87)Weighted average number of common shares outstanding, basic and diluted 10,174 9,651 # # #